<?xml version="1.0" encoding="UTF-8"?>
<p id="par0125">Emerging BSAAs, such as 5,6-dimethoxyindan-1-one, saliphenylhalamide, and GS-5734 (
 <xref rid="bib0110" ref-type="bibr">Denisova et al., 2012</xref>, 
 <xref rid="bib0245" ref-type="bibr">Kuivanen et al., 2017</xref>, 
 <xref rid="bib0325" ref-type="bibr">Muller et al., 2011</xref>, 
 <xref rid="bib0330" ref-type="bibr">Muller et al., 2014</xref>, 
 <xref rid="bib0350" ref-type="bibr">Patil et al., 2017</xref>, 
 <xref rid="bib0430" ref-type="bibr">Sheahan et al., 2017</xref>), whose safety profiles in humans are not yet available, are not included in the database. However, they could serve as valuable antivirals in the future, pending the results of further pre-clinical and clinical investigations.
</p>
